Summary
41 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 CNY of revenue, 27 CNY is left as free cash.
What to watch
- Revenue fell by 8.5% a year over the last 3 years.
- It pays out more in dividends than it earns: 102% of profit.
- It earns only 1.1 CNY a year on every 100 CNY of invested capital.
- Out of every 100 CNY of revenue, only 3.9 CNY is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 22.6 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 0.5% a year over 5 years. Over the last 3 years it fell by 8.5% a year. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 67 CNY
- Research and development 3.9 CNY
- Sales and administration 26 CNY
- Taxes and other 0.1 CNY
- Net profit 3.9 CNY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 CNY
Out of every 100 CNY of revenue, 3.9 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.1 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.51%
- Paid out of profit
- 102%
You receive $0.02 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.